Activin A and TGF-β stimulate phosphorylation of focal adhesion proteins and cytoskeletal reorganization in rat aortic smooth muscle cells

被引:38
作者
Riedy, MC
Brown, MC
Molloy, CJ
Turner, CE
机构
[1] SUNY Hlth Sci Ctr, Dept Anat & Cell Biol, Cell & Mol Biol Program, Syracuse, NY 13210 USA
[2] Bristol Myers Squibb Pharmaceut Res Inst, Princeton, NJ 08543 USA
关键词
paxillin; cytoskeleton; FAK; p130(cas); migration;
D O I
10.1006/excr.1999.4573
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Activin A and Transforming Growth Factor-beta (TGF-beta) are members of a common family of cytokines that bind to and stimulate serine/threonine kinase receptors. Activin A and TGF-beta are important during embryonic development exerting both positive and negative effects on cell growth. In the adult organism, they function in processes such as tissue repair, cellular proliferation, and differentiation. Although activin A and TGF-beta often induce opposite functional outcomes in specific cells; proliferation or differentiation, both were found to stimulate the. formation of actin stress fibers and focal adhesions in serum-starved rat aortic smooth muscle (RASM) cells, These structural changes were accompanied by phosphorylation of the focal adhesion proteins, paxillin, and p130(cas). Similar cytoskeletal and biochemical changes were observed with the vasoactive agonist angiotensin II. Activation of the ERK/MAP kinase pathway has been implicated in the migration in certain cell types, However, while activin A, TGF-beta, and angiotensin II all stimulated ERK activity in RASM cells, only activin A and angiotensin II stimulated migration. TGF-beta failed to illicit a chemotactic response. Furthermore,pharmacologic inhibition of MEK activity failed to block migration in response to activin A and angiotensin II, indicating RASM migration can occur independent of ERK activity. These results suggest that TGF-beta and activin A share several signaling pathways with angiotensin II leading to cytoskeletal remodeling and ERK activation, but there are distinct differences regarding the effect of these agonists on cellular migration. (C) 1999 Academic Press.
引用
收藏
页码:194 / 202
页数:9
相关论文
共 45 条
[1]   Adhesion of fibroblasts to fibronectin stimulates both serine and tyrosine phosphorylation of paxillin [J].
Bellis, SL ;
Perrotta, JA ;
Curtis, MS ;
Turner, CE .
BIOCHEMICAL JOURNAL, 1997, 325 :375-381
[2]   Angiotensin II signal transduction in vascular smooth muscle - Role of tyrosine kinases [J].
Berk, BC ;
Corson, MA .
CIRCULATION RESEARCH, 1997, 80 (05) :607-616
[3]   INSULIN-LIKE GROWTH-FACTOR-I AND PLATELET-DERIVED GROWTH FACTOR-BB INDUCE DIRECTED MIGRATION OF HUMAN ARTERIAL SMOOTH-MUSCLE CELLS VIA SIGNALING PATHWAYS THAT ARE DISTINCT FROM THOSE OF PROLIFERATION [J].
BORNFELDT, KE ;
RAINES, EW ;
NAKANO, T ;
GRAVES, LM ;
KREBS, EG ;
ROSS, R .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 93 (03) :1266-1274
[4]   Serine and threonine phosphorylation of the paxillin LIM domains regulates paxillin focal adhesion localization and cell adhesion to fibronectin [J].
Brown, MC ;
Perrotta, JA ;
Turner, CE .
MOLECULAR BIOLOGY OF THE CELL, 1998, 9 (07) :1803-1816
[5]   Identification of p130Cas as a mediator of focal adhesion kinase-promoted cell migration [J].
Cary, LA ;
Han, DC ;
Polte, TR ;
Hanks, SK ;
Guan, JL .
JOURNAL OF CELL BIOLOGY, 1998, 140 (01) :211-221
[6]   Integrin alpha(v)beta(5)-dependent serine phosphorylation of paxillin in cultured human macrophages adherent to vitronectin [J].
DeNichilo, MO ;
Yamada, KM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (18) :11016-11022
[7]   Intracellular signalling: The Mad way to do it [J].
Derynck, R ;
Zhang, Y .
CURRENT BIOLOGY, 1996, 6 (10) :1226-1229
[8]   ANGIOTENSIN-II SIGNAL-TRANSDUCTION AND THE MITOGEN-ACTIVATED PROTEIN-KINASE PATHWAY [J].
DUFF, JL ;
MARRERO, MB ;
PAXTON, WG ;
SCHIEFFER, B ;
BERNSTEIN, KE ;
BERK, BC .
CARDIOVASCULAR RESEARCH, 1995, 30 (04) :511-517
[9]  
Frey RS, 1997, CANCER RES, V57, P628
[10]   ANGIOTENSIN CONVERTING ENZYME-INHIBITION AND VASCULAR HYPERTROPHY IN HYPERTENSION [J].
GIBBONS, GH ;
DZAU, VJ .
CARDIOVASCULAR DRUGS AND THERAPY, 1990, 4 (01) :237-242